In the Clinic

Our lead investigational drug, OP-1250, is an estrogen receptor antagonist. It was developed to compete with estrogen for binding to the receptor and keep it in a completely inactive state.

OP-1250 is currently in development as a treatment for estrogen receptor-positive, HER2-negative metastatic breast cancer (ER+, HER2- MBC), in both monotherapy and combination settings.

OP-1250 Pipeline

Target Patient Population

Discovery

Nonclinical

Phase I

Phase II

Phase III

Clinical
Collaboration

Metastatic Breast Cancer

ER+, HER2- MBC (with and without CNS metastases)

ER+, HER2- MBC (combination with palbociclib)

ER+, HER2- MBC (combination with ribociclib)

ER+, HER2- MBC with PIK3CA mutated (combination with alpelisib)

ER+ with ESR1 mutation(1)

HER2+ Metastatic Breast Cancer with CNS METS

ER+, HER2+ MBC with CNS metastases

Gynecology — Oncology

Endometrial Cancer(1)

Gynecologic malignancies

Discovery Pipeline

Target Patient Population

Discovery

Nonclinical

Phase I

Phase II

Phase III

Clinical
Collaboration

Breast Cancer target

Undisclosed Oncology target

Clinical Trials

Our first clinical trial is an ongoing Phase 1/2, open-label, multi-center, dose-escalation, and expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of daily oral administration of OP-1250.

Get in Touch

Reach out for inquries regarding investor relations, media, clinical trials or general information.